AnnChildressMD

Psychiatry • Las Vegas, NV

Child & Adolescent Psychiatry

Physician

Join to view full profile

Dr. Childress is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Childress' full profile

Already have an account?

Office
4000 E Charleston Blvd
Ste 130
Las Vegas, NV 89104
Phone+1 702-968-4000

Fax+1 702-838-6749

Education & Training

Medical University of South CarolinaFellowship, Child and Adolescent Psychiatry, 1991 - 1993
Medical University of South CarolinaResidency, Psychiatry, 1987 - 1991
Medical University of South CarolinaClass of 1987

Certifications & Licensure

NV State Medical License 1997 - 2025
SC State Medical License 1988 - 1997
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD Start of enrollment: 2005 Jun 01
Completed
Phase 3
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD Start of enrollment: 2004 Sep 01
Completed
Phase 2
PEARL Schizophrenia Maintenance Start of enrollment: 2011 Sep 01
Completed
Phase 3
Lurasidone Pediatric Autism Study Start of enrollment: 2013 Aug 01
Completed
Phase 3
Pediatric Open-Label Extension Study Start of enrollment: 2013 Sep 30
Completed
Phase 3
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2014 Mar 01
Completed
Phase 3
PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
Completed
Phase 3
Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Completed
Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD Start of enrollment: 2014 May 01
Completed
Phase 3
PRC-063 in an ADULT Workplace Environment Start of enrollment: 2014 Aug 01
Completed
Phase 3
Dasotraline Pediatric ADHD Study Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
Dasotraline Pediatric Extension Study Start of enrollment: 2015 Jun 30
Completed
Phase 3
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder Start of enrollment: 2015 Aug 21
Completed
Phase 3
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Completed
Phase 3
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting Start of enrollment: 2015 Jul 01
Completed
Phase 3
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD Start of enrollment: 2016 Sep 01
Unknown status
Phase 4
Reference Database Development for the Quotient® System iPad Test Start of enrollment: 2016 Apr 01
Completed
Not Applicable
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension Start of enrollment: 2019 Oct 04
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment.
Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Yan Meng
Neurology and Therapy. 2024-11-16
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Ann Childress, Andrew J Cutler, Lenard A Adler, Nicholas Fry, Kobby Asubonteng
CNS Drugs. 2024-11-01
Clinical Implications of Attention-Deficit/Hyperactivity Disorder in Adults: What New Data on Diagnostic Trends, Treatment Barriers, and Telehealth Utilization Tell Us.
Gregory Mattingly, Ann Childress
The Journal of Clinical Psychiatry. 2024-10-10

Press Mentions

CDC: Half of People with ADHD Diagnosed in AdulthoodOctober 15th, 2024
Corium's Novel ADHD Medication AZSTARYS® (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth RateMay 22nd, 2023
A Once-Daily Stimulator for ADHD Is Safe, Effective for 1 YearMarch 10th, 2023
Join now to see all

AnnChildressMD

Dr. Childress is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.